YM BioSciences, Inc. (AMEX: YMI)

Sector: Medical

Current Price : $2.94

52 Week Low
$1.4952 Week High
$2.95

Press Releases
Final Six In-Fill Drill Holes Reported from the Winter Drill Program at Harper Creek
Yellowhead Mining Inc. Reports Financial and Operating Results for the Three Months Ended March 31, 2013
Eight In-Fill Drill Holes Reported from Recently Completed Drill Program in Central and Eastern Sections at Harper Creek
Harper Creek Submits Environmental Assessment Certificate Application
Yellowhead Mining Inc. Reports Financial and Operating Results for Fourteen Months Ended December 31, 2012
Ten In-Fill Drill Holes Complete Western Sections of Current Drill Program at Harper Creek
Seven In-Fill Drill Holes Continue to Add Confidence To Harper Creek Stratabound Resource
In-Fill Drill Holes Add Confidence To Harper Creek Stratabound Resource
Yellowhead Mining Engages Evercore Partners to Advise on a Formal Strategic Partnering Process in Connection with Harper Creek Project
Gilead Sciences Completes Acquisition of YM BioSciences
YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2013
Yellowhead Files Amended and Re-stated 43-101 Technical Report
YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement with Gilead Sciences
YM BioSciences Shareholders Approve Plan of Arrangement with Gilead Sciences
The Reason It Trades, What's Moving ANV, YMI and NAVB
Free Research Reports on CIM, JRCC, HOV and YMI Issued by the Bedford Report
YM BioSciences Inc. Plan of Arrangement with Gilead Sciences, Inc. Endorsed by Leading Independent Proxy Advisors ISS and Glass Lewis
Yellowhead announces partial closing of Private Placement
YM BioSciences Announces Record Date for Previously Announced Plan of Arrangement
Ian Smith Resigns as Yellowhead Director
Free Research Reports on CSTR, MSFT, SCMP and YMI Issued by the Bedford Report
Gilead Sciences to Acquire YM BioSciences
YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at ASH 2012
Yellowhead Announces Commencement of 11,000 m Drill Program
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
YM BioSciences Announces Election of Dr. Kapil Dhingra to its Board of Directors
Yellowhead Mining Inc. Reports Financial and Operating Results for Three and Eleven Months Ended September 30, 2012
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013
Yellowhead announces partial closing of Private Placement
YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses
Yellowhead Announces Private Placement Offering
Yellowhead announces appointment of Gregory Hawkins as Interim Chief Executive Officer
YM BioSciences Reports CYT387 Phase I/II Results Selected for Oral Presentation at ASH2012 Conference
Premier Christy Clark pledges support for North Thompson Power
Yellowhead Mining Inc. Reports Financial and Operating Results for Three and Eight Months Ended June 30, 2012
Yellowhead Mining Inc. Welcomes Ming An Fu to its Board
Yellowhead Mining Inc. Announces Graduation to TSX
Yellowhead Mining Inc. Reports Financial and Operating Results for Three and Five Months Ended March 31, 2012
Yellowhead Mining Inc. appoints Beverly A. Bartlett to board and grants stock options
Yellowhead Mining Inc. Announces Resignation of Director
Yellowhead Mining Inc. announces results of 2012 Annual General and Special Meeting of Shareholders and Granting of Stock Options to Directors and Officers
Yellowhead Mining Appoints O&M Partners, LLC, New York
Yellowhead Mining Files Feasibility Study on SEDAR
Yellowhead Mining Adopts Shareholder Rights Plan
Yellowhead Mining Reports Completion of Feasibility Study; Confirms Robust Economics Over a 28 Year Project Life
YM BioSciences Raises US$80.5 Million from Public Offering
Yellowhead Mining Inc. Reports Financial and Operating Results for Two Months Ended December 31, 2011
YM BioSciences Prices $70 Million Public Offering of Common Shares
YM BioSciences Announces Proposed Public Offering of Common Shares
Yellowhead Mining Inc. Retains Bay Street Connect
Yellowhead Mining Inc. Reports Step-Out and In-Fill Drill Results from 2011 Program
Yellowhead Mining Inc. Changes Financial Year End
Mining Updates Mineral Resource Estimate for Harper Creek Project
Yellowhead Mining Inc. appoints Cliveden AG for Marketing Advisory Services
YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
YM BioSciences and AEterna Zentaris -- Starting Strong in 2012
YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011
YM BioSciences Comments on Unusual Market Activity
Yellowhead Mining Inc. purchases abandoned Weyerhauser mill property in Vavenby with rail siding for concentrate load-out
YM BioSciences to Report Updated Phase I/II Data for CYT387 at ASH 2011
Yellowhead Mining Inc. to present at Canada Mineral Investment Forum in Beijing and attend China Mining 2011 in Tianjin
Yellowhead Mining Inc. to present at Canada Mineral Investment Forum in Beijing and attend China Mining 2011 in Tianjin
YM BioSciences Nimotuzumab Results Reported at SIOP Conference
Yellowhead Mining Inc. Reports Comminution and Flotation Testwork Results
BC Environmental Assessment Office approves Application Information Requirements for Harper Creek Project
YM BioSciences Proposes Dr. Catherine Mackey and Dr. Nicole Onetto for Nomination to Board of Directors
YM BioSciences Initiates Phase II BID Trial with CYT387 in Myelofibrosis
YM BioSciences Announces Nimotuzumab Data to be Reported at 2011 ECCO-ESMO Conference
CORRECTION FROM SOURCE: YM BioSciences Reports Fiscal 2011 Year End Operational and Financial Results
Yellowhead Mining Inc. Reports Financial and Operating Results to July 31, 2011
YM BioSciences Reports Fiscal 2011 Year End Operational and Financial Results
YM BioSciences JAK Inhibitor CYT387 Shown Active in Multiple Myeloma
YM BioSciences Files Preliminary Base Shelf Prospectus
Changing of the Guard Begins in Biotech Sector
YM BioSciences Reports Interim Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASCO
Yellowhead Mining Inc. Appoints VP Environment, Community & First Nations Relations; Also Manager, Corporate Administration
YM BioSciences Announces Orphan Drug Designation for JAK1/JAK2 Inhibitor CYT387 in Europe
YM BioSciences Provides Update on the Development Program for Nimotuzumab
Yellowhead Mining Inc.: Drill Hole HC11-87 Returned Best Intersection to Date at Harper Creek
YM BioSciences Reports Updated 12-Week Phase I/II Results for its JAK1/JAK2 Inhibitor CYT387
YM BioSciences Reports Fiscal Third Quarter 2011 Operational and Financial Results
Harper Creek Drill Holes HC11-83 and HC11-84 Confirm Mineralization 500m Beyond Northern Limit of Drill Holes in PEA Resource Model; Historical Resampling Continues
YM BioSciences Reports Positive Updated Anemia Response Data for its JAK1/JAK2 Inhibitor CYT387 Disclosed at First Annual Florence Meeting on Myeloproliferative Neoplasms in Florence, Italy
Yellowhead Mining Announces Closing of Over-Allotment Option and Non-Brokered Private Placement of Units
Yellowhead Mining Awards Feasibility Study to Merit Consultants International Inc. and Environmental Assessment and Geotechnical Program to Knight Piesold Limited
Yellowhead Mining Announces Closing of Bought Deal Private Placement for Gross Proceeds of CDN$20,488,000
Yellowhead Mining Inc. Appoints New Advisors to the Board
Speculative Biotech Firms Grapple With Difficult Approval Process
Yellowhead Mining Inc. Announces CDN$20 Million Bought Deal Private Placement
Yellowhead Mining Reports Positive Results of Preliminary Economic Assessment
Yellowhead Mining Inc.: Harper Creek Drill Hole HC10-82 Confirms Mineralization Beyond Northern Limit of Drill Holes in 2010 Resource Model
Yellowhead Mining Inc.: Harper Creek Drill Hole HC10-80 Confirms Mineralization Beyond Eastern Limit of Drill Holes in 2010 Resource Model
YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium

iStock Rating

YM BioSciences, Inc. (AMEX: YMI)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios